NeoRx to Hold 2004 Second Quarter Financial Results Conference Call

HostReview.com
Wednesday, July 28, 2004; 12:00 AM

SEATTLE--(BUSINESS WIRE)--July 28, 2004--NeoRx Corporation (NASDAQ:NERX), a cancer therapeutics development company, today announced that the Company will release 2004 second quarter financial results before market open on Tuesday, August 3, 2004.

Management will be hosting an investment-community conference call beginning at 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time) on Tuesday, August 3 to discuss the results and answer questions.

To participate in the live call by telephone, please dial (888) 803-8271 from the U.S., and for international callers, please dial (706) 634-2467. A telephone replay will be available for 48 hours following the conclusion of the call by dialing (800) 642-1687 from the U.S., or (706) 645-9291 for international callers, and entering reservation number 9012881.

The live conference call will also be available to private investors via the Internet at www.neorx.com, and a recording of the call will be available on the Company's Web site for 14 days following the completion of the call.

NeoRx, a cancer therapeutics development company, opened enrollment in a phase III clinical trial of STR in patients with multiple myeloma in March 2004. In April 2004, NeoRx acquired the rights to develop, manufacture and commercialize Nexplatin, a third-generation platinum-based anti-cancer agent. The Company plans to initiate phase II clinical studies of Nexplatin in one or more cancer indications next year.

This release contains forward-looking statements relating to the development of the Company's products and strategic goals that are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected. The words "believe," "expect," "intend," "anticipate," "plan," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect the Company's actual results include conditions in the capital markets in general and in the life science sector in particular, specifically those that may affect potential financing sources for the development of NeoRx's business, the progress and costs of clinical trials and the timing of regulatory approvals, the availability of clinical materials from third-party suppliers, NeoRx's ability to manufacture STR in a timely and cost-effective manner, NeoRx's ability to successfully commercialize product candidates, and other risks and uncertainties described in NeoRx's current and periodic reports filed with the Securities and Exchange Commission, including NeoRx's Annual Report on Form 10-K for the year ended December 31, 2003, and Quarterly Report on Form 10-Q for the quarter ended March 31, 2004. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update any forward-looking statement to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.

NeoRx and STR are trademarks or registered trademarks of NeoRx Corporation in the United States and/or foreign countries.

(C) 2004 NeoRx Corporation. All Rights Reserved.

CONTACT: NeoRx Corporation Jerry McMahon, 206-286-2524 Lippert/Heilshorn & Associates, Inc. Jody Cain (jcain@lhai.com) Bruce Voss (bvoss@lhai.com) 310-691-7100 SOURCE: NeoRx Corporation "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding NeoRx's business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's Annual Report or Form 10-K for the most recently ended fiscal year.